Treatment of glioblastoma in elderly patients: An overview of current treatments and future perspective

Tumori

Volumn 96, Issue 5, 2010, Pages 650-658

  Lanzetta, Gaetano ^a   Minniti, Giuseppe ^a,b  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chemotherapy; Elderly; Glioblastoma; Radiotherapy; Surgery; Temozolomide

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEDIRANIB; CILENGITIDE; CYTOSTATIC AGENT; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; IRINOTECAN; LOMUSTINE; LONAFARNIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROCARBAZINE; SORAFENIB; STEROID; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; VANDETANIB; VASCULOTROPIN RECEPTOR; VATALANIB; VINCRISTINE;

ADD ON THERAPY; ADJUVANT THERAPY; AGED; ANTIANGIOGENIC THERAPY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COGNITIVE DEFECT; CYTOREDUCTIVE SURGERY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; LONG TERM CARE; MENTAL DETERIORATION; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROSURGERY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; STEREOTAXIC SURGERY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT INDICATION; TUMOR BIOPSY; TUMOR RECURRENCE;

EID: 78650429307     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600502     Document Type: Review

References (75)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol, 2: 533-543, 2001.
2. Cancer Facts & Figures 2005, In: Surveillance Research, pp 1-60, American Cancer Society, Atlanta, 2005.
3. Jukich PJ, McCarthy BJ, Surawicz TS, Freels S, Davis FG: Trends in incidence of primary brain tumors in the United States, 1985-1994. Neuro Oncol, 3: 141-151, 2001.
4. Johannesen TB, Angell-Andersen E, Tretli S, Langmark F, Lote K: Trends in incidence of brain and central nervous system tumors in Norway, 1970-1999. Neuroepidemiology, 23: 101-111, 2004.
5. Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston- Martin S: A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer, 104: 2798-2806, 2005.
6. Davis FG, Freels S, Grutsch J, Barlas S, Brem S: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg, 88: 1-10, 1998.
7. Greig NH, Ries LG, Yancik R, Rapoport SI: Increasing annual incidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst, 82: 1621-1624, 1990.
8. Mao Y, Desmeules M, Semenciw RM, Hill G, Gaudette L, Wigle DT: Increasing brain cancer rates in Canada. Can Med Assoc J, 145: 1583-1591, 1991.
9. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS: Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys, 26: 239-244, 1993.
10. Laws ER, Shaffrey ME, Morris A, Anderson FA Jr: Surgical management of intracranial gliomas - does radical resection improve outcome? Acta Neurochir Suppl, 85: 47-53, 2003.
11. Keles GE, Anderson B, Berger MS: The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol, 52: 371-379, 1999.
12. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg, 95: 190-198, 2001.
13. Brown PD, Maurer MJ, Rummans TA, Pollock BE, Ballman KV, Sloan JA, Boeve BF, Arusell RM, Clark MM, Buckner JC: A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery, 57: 495-504, 2005.
14. Mitchell P, Ellison DW, Mendelow AD: Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurol, 4, 413-422, 2005.
15. Litofsky NS, Bauer AM, Kasper RS, Sullivan CM, Dabbous OH: Glioma Outcome Project Investigators. Image-guided resection of high-grade glioma: patient selection factors and outcome. Neurosurg Focus, 20, E16, 2006.
16. Mineo JF, Bordron A, Baroncini M, Ramirez C, Maurage CA, Blond S, Dam-Hieu P: Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir (Wien), 149: 245-252, 2007.
17. Sanai N, Berger MS: Glioma extent of resection and its impact on patient outcome. Neurosurgery, 62: 753-764, 2008.
18. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T; ALA-Glioma Study Group: Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery, 62, 564-576, 2008.
19. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ; ALA-Glioma Study Group: ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol, 7: 392-401, 2006.
20. Vuorinen V, Hinkka S, Färkkilä M, Jääskeläinen J: Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien), 145: 5-10, 2003.
21. Kelly PJ, Hunt C: The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery, 34: 62-66, 1994.
22. Quigley MR, Maroon JC: The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery, 29: 385-388, 1991.
23. Hess KR: Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol, 42: 227-231, 1999.
24. Vives KP, Piepmeier JM: Complications and expected outcome of glioma surgery. J Neurooncol, 42: 289-302, 1999.
25. Metcalfe SE, Grant R: Biopsy versus resection for malignant glioma. Cochrane Database Syst Rev, 3: CD002034, 2001.
26. Bauman GS, Gaspar LE, Fisher BJ, Halperin EC, Macdonald DR, Cairncross JG: A prospective study of short course RT in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 29: 835-839, 1994.
27. Ford JM, Stenning SP, Boote DJ, Counsell R , Falk SJ, Flavin A , Laurence VM, Bleehen NM: A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma. Clin Oncol (R Coll Radiol), 9: 20-24, 1997.
28. Hoegler DB, Davey P: A prospective study of short course radiotherapy in elderly patients with malignant glioma. J Neurooncol, 33: 201-214, 1997.
29. Mohan DS, Suh JH, Phan JL, Kupelian PA, Cohen BH, Barnett GH: Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol Biol Phys, 42: 981-987, 1998.
30. Villà S, Viñolas N, Verger E, Yaya R, Martínez A, Gil M, Moreno V, Caral L, Graus F: Efficacy of radiotherapy for malignant gliomas in elderly patients. Int J Radiat Oncol Biol Phys, 42: 977-980, 1998.
31. Pierga JY, Hoang-Xuan K, Feuvret L, Simon JM, Cornu P, Baillet F, Mazeron JJ, Delattre JY: Treatment of malignant gliomas in the elderly. J Neurooncol, 43: 187-193, 1999.
32. Brandes AA, Vastola F, Basso U: A prospective study in glioblastoma multiforme. Cancer, 3: 657-662, 2003.
33. Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD: Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer, 97: 2262-2266, 2003.
34. McAleese JJ, Stenning SP, Ashley S Traish D, Hines F, Sardell S, Guerrero D, Brada M: Hypofractionated radiotherapy for poor prognosis malignant glioma: matched pair survival analysis with MRC controls. Radiother Oncol, 67: 177-182, 2003.
35. Roa W, Brasher PMA, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A, Petruk K, Stewart D, Tai P, Urtasun R, Cairncross JG, Forsyth P: Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol, 22: 1593-1598, 2004.
36. Marijnen CA, van den Berg SM, van Duinen SG, Voormolen JH, Noordijk EM: Radiotherapy is effective in patients with glioblastoma multiforme with a limited prognosis and in patients above 70 years of age: a retrospective single institution analysis. Radiother Oncol, 75: 210-216, 2005.
37. Keime-Guiber F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY, Meneï P, Loiseau H, Bernier V, Honnorat J, Barrié M, Mokhtari K, Mazeron JJ, Bissery A, Delattre JY; Association of French-Speaking Neuro-Oncologists: Radiotherapy for glioblastoma in the elderly. N Engl J Med, 356: 1527-1535, 2007.
38. Thomas R, James N, Guerrero D, Ashley S, Gregor A, Brada M: Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Radiother Oncol, 33: 113-116, 1994.
39. Whittle IR, Basu N, Grant R, Walker M, Gregor A: Management of patients aged >60 years with malignant glioma: good clinical status and radiotherapy determine outcome. Br J Neurosurg, 16: 343-347, 2002.
40. Laperriere N, Zuraw L, Cairncross G: Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol, 64: 259-273, 2002.
41. Bleehen NM, Stenning SP: A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer, 64: 769-774, 1991.
42. Chinot OL, Barrie M, Frauger E, Dufour H, Figarella-Branger D, Palmari J, Braguer D, Hoang-Xuan K, Moktari K, Peragut J-CC, Martin P-MM, Grisoli F: Phase II study of zemozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population. Cancer, 100: 2208-2214, 2004.
43. Chamberlain MC, Chalmers L: A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. J Neurooncol, 82: 207-209, 2007.
44. Stupp R, Mason W, Van der Bent M, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352: 987-996, 2005.
45. Minniti G, De Sanctis V, Muni R, Filippone F, Bozzao A, Valeriani M, Osti MF, De Paula U, Lanzetta G, Tombolini V, Maurizi Enrici R: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol, 88: 97-103, 2008.
46. Sijben AE, McIntyre JB, Roldán GB, Easaw JC, Yan E, Forsyth PA, Parney IF, Magliocco AM, Bernsen H, Cairncross JG: Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol, 89: 97-103, 2008.
47. Combs SE, Wagner J, Bischof M, Welzel T, Wagner F, Debus J, Schulz-Ertner D: Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys, 70: 987-992, 2008.
48. Piccirilli M, Bistazzoni S, Gagliardi FM, Landi A, Santoro A, Giangaspero F, Salvati M: Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years. Tumori, 92: 98-103, 2006.
49. Minniti G, De Sanctis V, Muni R, Rasio D, Lanzetta G, Bozzao A, Osti MF, Salvati M, Valeriani M, Cantore GP, Maurizi Enrici R: Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol, 91: 95-100, 2009.
50. Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M: Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer, 115: 3512-3518, 2009.
51. Maire JP, Coudin B, Guérin J, Caudry M: Neuropsychologic impairment in adults with brain tumors. Am J Clin Oncol, 10: 156-162, 1987.
52. Stylopoulos LA, George AE, de Leon MJ, Miller JD, Foo SH, Hiesiger E, Wise A: Longitudinal CT study of parenchymal brain changes in glioma survivors. Am J Neuroradiol, 9: 517-522, 1988.
53. Grant R, Liang BC, Page MA, Crane DL, Greenberg HS, Junck L: Age influences chemotherapy response in astrocytomas. Neurology, 45: 929-933, 1995.
54. Gilbert M, O'Neill A, Grossman S, Grunnet M, Mehta M, Jubelirer S, Hellman R: A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: an Eastern Cooperative Oncology Group study (E2393). J Neurooncol, 47: 145-152, 2000.
55. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 352: 997-1003, 2005.
56. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R: Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol, 9; 29-38, 2008.
57. Sanson M, Thillet J, Hoang-Xuan K: Molecular changes in gliomas. Curr Opin Oncol, 16: 607-613, 2004.
58. Louis DN: Molecular pathology of malignant gliomas. Annu Rev Pathol, 1: 97-117, 2006.
59. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol, 22: 133-142, 2004.
60. Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page MS, Fedoroff A, Xie D, Kelley SK: Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol, 8: 67-78, 2006.
61. Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J: Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol, 61: 1059-1067, 2008.
62. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med, 353: 2012-2024, 2005.
63. Haas-Kogan DA, Prados MD, Lamborn KR, Tihan T, Berger MS, Stokoe D: Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle, 4: 1369-1372, 2005.
64. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst, 97: 880-887, 2005.
65. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM Jr, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C, Buckner JC; North Central Cancer Treatment Group Study N0177: Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol, 26: 5603-5609, 2008.
66. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol, 27: 579-584, 2009.
67. nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol, 25: 4722-4729, 2007.
68. nd , Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res, 13: 1253-1259, 2007.
69. Ali SA, McHayleh WM, Ahmad A, Sehgal R, Braffet M, Rahman M, Bejjani G, Friedland DM: Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg, 109: 268-272, 2008.
70. nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ: Bevacizumab Plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res, 14: 7068-7073, 2008.
71. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T: Phase II pilot study of bevacizumabin combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys, 71: 1372-1380, 2008.
72. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB: Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol, 26(34): 5610-5617, 2008.
73. Stupp R, Goldbrunner B, Neyns B, Schlegel U, Clement P, Grabenbauer GG, Hegi ME, Nippgen J, Picard M, Weller M: Phase I/II trial of celingitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma (GBM). J Clin Oncol (Meeting Abstracts), 2007; 25: 2000.
74. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN: Molecularly targeted therapy for malignant glioma. Cancer, 110: 13-24, 2007.
75. Stupp R, Hegi ME, Gilbert MR, Chakravarti A: Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol, 25: 4127-4136, 2007.